Guardant Health, Inc.

GHSEC EDGAR

Services-Medical Laboratories(DE)CIK: 1576280

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$563.9M	—	—	—	—
Cost of Goods and Services Sold	$227.1M	—	—	—	—
Research and Development Expense	$367.2M	$373.8M	$263.2M	$149.9M	$86.3M
Operating Income (Loss)	-$564.7M	-$544.4M	-$411.0M	-$254.9M	-$82.4M
Interest Expense	—	—	$2.6M	$4.8M	$1.2M
Other Nonoperating Income (Expense)	$53.2M	-$12.8M	$25.2M	$3.6M	$88.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$478.8M	-$653.4M	-$384.5M	-$245.9M	-$69.7M
Income Tax Expense (Benefit)	$685.0K	$1.1M	$300.0K	$379.0K	-$1.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.5B	$1.8B	$1.6B	$2.2B	$2.3B
Assets, Current	$1.1B	$1.3B	$1.2B	$1.1B	$1.9B
Cash and Cash Equivalents, at Carrying Value	$1.1B	$141.6M	$492.2M	$492.2M	$833.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$110.3M	$88.8M	$97.3M	$97.7M	$53.3M
Inventory, Net	$71.1M	$61.9M	$51.6M	$30.7M	$22.7M
Liabilities	$1.6B	$1.6B	$1.5B	$1.6B	$916.2M
Liabilities, Current	$225.6M	$205.9M	$193.2M	$194.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$325.0M	-$309.5M	-$209.0M	-$103.9M	-$47.1M
Net Cash Provided by (Used in) Investing Activities	$840.3M	$149.8M	-$63.2M	-$617.1M	-$317.6M
Net Cash Provided by (Used in) Financing Activities	$477.4M	-$189.1M	-$66.8M	$1.4B	$367.3M
Payments to Acquire Property, Plant, and Equipment	$20.5M	$77.5M	$75.0M	$36.2M	$18.7M
Payments for Repurchase of Common Stock	$0.00	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)